BCL2 and neoplasm: Subsequently, the deficiency of miR-338-5p in hypoxic cancer cells moderated the decrease in IL-6 expression and reactivated the anti-apoptotic STAT3/Bcl2 signaling pathway, thus impeding tumor cell death and improving the drug resistance of tumor cells.54